rs1071816 - HLA-B: antithyroid drug risk
Upload your raw genetic data once, we'll show you which variants you carry and what the research says.
Key takeaways
- rs1071816 is linked to antithyroid drug-induced agranulocytosis
- the variant shows a reported effect size of 5.27 p=2.35e-9 in European adults
- it is in moderate linkage disequilibrium with HLA-B*27:05
Key takeaways
- rs1071816 is linked to antithyroid drug-induced agranulocytosis
- the variant shows a reported effect size of 5.27 p=2.35e-9 in European adults
- it is in moderate linkage disequilibrium with HLA-B*27:05
What the research says rs1071816 is associated with antithyroid drug-induced agranulocytosis in European adults with a reported effect size of 5.27 p=2.35e-9 [PMID 27157822]. Also the variant is linked to HLA-B*27:05 which is on chromosome 6 [PMID 27157822].
Reported associations Antithyroid drug-induced agranulocytosis the rs1071816 variant is linked to a higher risk of this condition in European adults with an odds ratio of 5.27 (p=2.35e-9) [PMID 27157822]. HLA-B*27:05 the variant is in moderate linkage disequilibrium with this allele and also associated with agranulocytosis [PMID 27157822].
Evidence quality the study enrolled 234 European adults with drug-induced agranulocytosis and 5170 population controls [PMID 27157822]. A genome-wide significance threshold of p<5e-8 was used. The variant rs1071816 showed a significant association (p=2.35e-9) with antithyroid drug-induced agranulocytosis and is in moderate linkage disequilibrium with HLA-B*27:05 [PMID 27157822]. No conflicting findings were reported.
Drug response and pharmacogenomics Antithyroid preparations patients with CC genotype may have increased risk of agranulocytosis compared to CT or TT [PMID 27157822]. Antithyroid preparations patients with CT genotype may have increased risk of agranulocytosis compared to TT but decreased compared to CC [PMID 27157822]. Antithyroid preparations patients with TT genotype may have a decreased risk of agranulocytosis compared to CT or CC [PMID 27157822].
Lifestyle considerations No lifestyle considerations on file for this variant.
Lifestyle context
Concrete actions anchored to the cited research. We do not prescribe, we describe.
Discuss with your doctor
-
antithyroid drug safety before hyperthyroidism treatment Moderate
Variant rs1071816 in HLA-B region increases risk of agranulocytosis (critically low white blood cell count) during antithyroid drug therapy.
Before taking antithyroid drugs (thiamazole, carbimazole, propylthiouracil), discuss risk with prescriber.
Frequently asked questions
What does rs1071816 mean?
It is a single nucleotide change near the HLA-B gene that has been associated with higher risk of agranulocytosis when people take antithyroid drugs. No personal advice given.
Is this variant linked to any other health issues?
The study only found an association with drug-induced agranulocytosis and a moderate link to the HLA-B*27:05 allele on chromosome 6. No evidence for other conditions.
Can I avoid this risk?
There is no recommendation to change diet or lifestyle; the variant itself does not cause disease but may increase susceptibility under certain drug exposure.